Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.

Anderson PL, Fletcher CV.

Curr HIV/AIDS Rep. 2004 Apr;1(1):33-9. Review.

PMID:
16091221
2.

Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.

Anderson PL, Fletcher CV.

Curr Infect Dis Rep. 2001 Aug;3(4):381-387.

PMID:
11470030
3.

High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.

Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet AM; COPHAR1-ANRS 102 Study Group..

Clin Pharmacokinet. 2005;44(12):1267-78.

PMID:
16372824
4.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
5.

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

Masquelier B, Peytavin G, Leport C, Droz C, Duran S, Verdon R, Besnier JM, Chêne G, Raffi F, Brun-Vézinet F; APROCO Study Group..

J Infect Dis. 2002 Nov 15;186(10):1503-7.

PMID:
12404170
6.

Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.

Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH.

Pediatr Infect Dis J. 2006 Jun;25(6):538-43.

PMID:
16732153
7.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group..

Clin Infect Dis. 2007 Jun 1;44(11):1484-92.

PMID:
17479947
8.

Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients.

Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chêne G, Préau M, de Boever CM, Leport C, Raffi F; Antiprotease Cohort (APROCO) Study Group..

J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):497-9.

PMID:
14657760
9.

Predictors of virologic response to ritonavir-boosted protease inhibitors.

Marcelin AG, Flandre P, Peytavin G, Calvez V.

AIDS Rev. 2005 Oct-Dec;7(4):225-32. Review.

PMID:
16425962
10.

Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1-infected children.

Burger DM, Bergshoeff AS, De Groot R, Gibb D, Walker S, Tréluyer JM, Hoetelmans RM; PENTA 5 study group..

J Pediatr. 2004 Sep;145(3):403-5.

PMID:
15343199
11.

Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.

King MS, Rode R, Cohen-Codar I, Calvez V, Marcelin AG, Hanna GJ, Kempf DJ.

Antimicrob Agents Chemother. 2007 Sep;51(9):3067-74. Erratum in: Antimicrob Agents Chemother. 2008 Feb;52(2):811.

14.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
15.

The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.

Maillard A, Chapplain JM, Tribut O, Bentué-Ferrer D, Tattevin P, Arvieux C, Michelet C, Ruffault A.

J Clin Virol. 2007 Feb;38(2):131-8.

PMID:
17208042
16.

Repeated measures analyses of dose timing of antiretroviral medication and its relationship to HIV virologic outcomes.

Liu H, Miller LG, Golin CE, Hays RD, Wu T, Wenger NS, Kaplan AH.

Stat Med. 2007 Feb 28;26(5):991-1007.

PMID:
16755546
17.

Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.

Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, Rockstroh JK.

Eur J Clin Pharmacol. 2007 Oct;63(10):901-8.

PMID:
17690876
18.
19.

The intracellular pharmacology of antiretroviral protease inhibitors.

Ford J, Khoo SH, Back DJ.

J Antimicrob Chemother. 2004 Dec;54(6):982-90. Review.

PMID:
15537695
20.

Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.

Scherpbier HJ, Bekker V, van Leth F, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2006 Mar;117(3):e528-36.

PMID:
16481448

Supplemental Content

Support Center